Supernus Pharmaceuticals (SUPN) Gross Margin (2013 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Gross Margin of 84.63% for Q2 2026, down 520.0% year-over-year from 20.15% in Q2 2025, and down 5.04% on a QoQ basis from 89.13% in Q4 2025.
Supernus Pharmaceuticals (SUPN) Gross Margin (2013 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Gross Margin for 14 years, with the latest figure at 84.63% in Q2 2026.
- Gross Margin for Q2 2026 came in at 84.63%, down 520.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 88.27% (down 26.0% YoY), and the FY2025 annual result was 89.63%, up 140.0% from the prior year.
- Gross Margin eased to 84.63% in Q2 2026, from 89.13% in the prior quarter.
- Over five years, Gross Margin peaked at 90.13% in Q3 2025 and troughed at 84.44% in Q2 2023.
- A 5-year average of 87.57% and a median of 88.06% in 2023 frame the typical range for Gross Margin.
- The widest annual swing landed in 2022, when Gross Margin soared 568 bps; it then slumped 520 bps in 2026.
- A 5-year view of Gross Margin shows it stood at 86.28% in 2022, then gained by 2 bps to 88.06% in 2023, then declined by 3 bps to 85.01% in 2024, then advanced by 5 bps to 89.13% in 2025, then decreased by 5 bps to 84.63% in 2026.
- Per Business Quant data, the three most recent Gross Margin figures were 84.63% in Q2 2026, 89.13% in Q4 2025, and 90.13% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | 84.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.63% |
| Dec 31, 2025 | 89.13% |
| Sep 30, 2025 | 90.13% |
| Jun 30, 2025 | 89.83% |
| Mar 31, 2025 | 89.48% |
| Dec 31, 2024 | 85.01% |
| Sep 30, 2024 | 89.99% |
| Jun 30, 2024 | 89.36% |
| Mar 31, 2024 | 88.65% |
| Dec 31, 2023 | 88.06% |
| Sep 30, 2023 | 87.26% |
| Jun 30, 2023 | 84.44% |
| Mar 31, 2023 | 84.74% |
| Dec 31, 2022 | 86.28% |
| Sep 30, 2022 | 85.41% |
| Jun 30, 2022 | 87.97% |
| Mar 31, 2022 | 88.24% |
| Dec 31, 2021 | 89.32% |
| Sep 30, 2021 | 87.82% |
| Jun 30, 2021 | 82.29% |